[1] [1] ISRAELSEN M, FRANCQUE S, TSOCHATZIS E A, et al. Steatotic liver disease[J]. Lancet, 2024, 404(10464): 1761-1778.

[2] [2] FERGUSON D, FINCK B N. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2021, 17(8): 484-495.

[3] [3] ESLAM M, NEWSOME P N, SARIN S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209.

[4] [4] BIKLE D, CHRISTAKOS S. New aspects of vitamin D metabolism and action—addressing the skin as source and target[J]. Nat Rev Endocrinol, 2020, 16: 234-252.

[5] [5] ZHAO S Y, QIAN F, WAN Z Z, et al. Vitamin D and major chronic diseases[J]. Trends Endocrinol Metab, 2024, 35(12): 1050-1061.

[6] [6] VON ESSEN M R, KONGSBAK M, SCHJERLING P, et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells[J]. Nat Immunol, 2010, 11(4): 344-349.

[7] [7] CHAUSS D, FREIWALD T, MCGREGOR R, et al. Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells[J]. Nat Immunol, 2022, 23(1): 62-74.

[8] [8] UDOMSINPRASERT W, JITTIKOON J. Vitamin D and liver fibrosis: molecular mechanisms and clinical studies[J]. Biomed Pharmacother, 2019, 109: 1351-1360.

[9] [9] LU W Y, LI X F, LIU N, et al. Vitamin D alleviates liver fibrosis by inhibiting histidine-rich calcium binding protein (HRC)[J]. Chem Biol Interact, 2021, 334: 109355.

[10] [10] HUANG G R, WEI S J, HUANG Y Q, et al. Mechanism of combined use of vitamin D and puerarin in anti-hepatic fibrosis by regulating the Wnt/-catenin signalling pathway[J]. World J Gastroenterol, 2018, 24(36): 4178-4185.

[11] [11] JI Y, WEI C B, GU W, et al. Relevance of vitamin D on NAFLD and liver fibrosis detected by vibration controlled transient elastography in US adults: a cross-sectional analysis of NHANES 2017-2018[J]. Ann Med, 2023, 55(1): 2209335.

[12] [12] WAN B, GAO Y, ZHENG Y S, et al. Association between serum 25-hydroxy vitamin D level and metabolic associated fatty liver disease (MAFLD)-a population-based study[J]. Endocr J, 2021, 68(6): 631-637.

[13] [13] KITSON M T, ROBERTS S K. D-livering the message: the importance of vitamin D status in chronic liver disease[J]. J Hepatol, 2012, 57(4): 897-909.

[16] [16] KARLAS T, PETROFF D, SASSO M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis[J]. J Hepatol, 2017, 66(5): 1022-1030.

[17] [17] IGNAT M, STEFANESCU H. Non-invasive biomarkers for differentiating alcohol associated hepatitis from acute decompensation in patients with ALD[J]. J Clin Med, 2024, 13(13): 3747.

[18] [18] LOMONACO R, GODINEZ LEIVA E, BRIL F, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening[J]. Diabetes Care, 2021, 44(2): 399-406.

[19] [19] PAN J, ZHOU Y J, PANG N Z, et al. Dietary niacin intake and mortality among individuals with nonalcoholic fatty liver disease[J]. JAMA Netw Open, 2024, 7(2): e2354277.

[20] [20] REBELOS E, TENTOLOURIS N, JUDE E. The role of vitamin D in health and disease: a narrative review on the mechanisms linking vitamin D with disease and the effects of supplementation[J]. Drugs, 2023, 83(8): 665-685.

[21] [21] YANG B B, CHEN Y H, ZHANG C, et al. Low vitamin D status is associated with advanced liver fibrosis in patients with nonalcoholic fatty liver disease[J]. Endocrine, 2017, 55(2): 582-590.

[22] [22] FANG J X, HAN Y, MENG J, et al. Relationship between non-alcoholic fatty liver and progressive fibrosis and serum 25-hydroxy vitamin D in patients with type 2 diabetes mellitus[J]. BMC Endocr Disord, 2024, 24(1): 108.

[23] [23] KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166.

[24] [24] ARAI T, ATSUKAWA M, TSUBOTA A, et al. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Dig Liver Dis, 2019, 51(7): 1036-1042.

[25] [25] LUKENDA ZANKO V, DOMISLOVIC V, TRKULJA V, et al. Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: a randomized, double-blind, placebo-controlled trial[J]. Diabetes Obes Metab, 2020, 22(11): 2097-2106.